Stock Events

Moderna 

ARS9,200
1930
+ARS50+0.55% Friday 19:53

Statistics

Day High
9,660
Day Low
8,800
52W High
11,150
52W Low
7,000
Volume
1,445
Avg. Volume
913
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-3,335.95
-1,926.45
-516.96
892.54
Expected EPS
-3117.62491
Actual EPS
-2696.086894

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MRNA.BA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.95B
Pfizer is a direct competitor in the COVID-19 vaccine market, with its mRNA vaccine developed in collaboration with BioNTech.
BioNTech
BNTX
Mkt Cap19.04B
BioNTech SE partnered with Pfizer to develop a COVID-19 mRNA vaccine, competing directly with Moderna's mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap352.53B
Johnson & Johnson competes in the COVID-19 vaccine space with its viral vector vaccine, offering an alternative to mRNA vaccines.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca competes with Moderna with its COVID-19 vaccine developed in collaboration with Oxford University, using a different technology (viral vector).
Novavax
NVAX
Mkt Cap1.67B
Novavax offers a protein subunit COVID-19 vaccine, providing an alternative to Moderna's mRNA vaccine.
Sanofi
SNY
Mkt Cap125.78B
Sanofi, through its partnership with GlaxoSmithKline, is developing COVID-19 vaccines that compete with Moderna's offerings.
GSK
GSK
Mkt Cap80.5B
GlaxoSmithKline, in collaboration with Sanofi, is working on COVID-19 vaccines, positioning it as a competitor to Moderna.
CureVac N.V.
CVAC
Mkt Cap736.57M
CureVac competes in the mRNA space, focusing on developing mRNA-based vaccines and therapeutics, including for COVID-19.
Merck &
MRK
Mkt Cap320.27B
Merck is involved in the development of COVID-19 treatments and vaccines, making it a competitor in the broader infectious disease market.
Abbott Laboratories
ABT
Mkt Cap180.96B
Abbott Laboratories competes with Moderna in the broader healthcare sector, including diagnostics and medical devices for infectious diseases.

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Stephane Bancel
Employees
5600
Country
US
ISIN
AR0666228538

Listings